Current Trends in Venture Capital • 18/06/2025 Understanding the Scale of Norwest Venture Capital Investments
The Future of Venture Capital • 12/06/2025 The Strategic Implications of Houzz's Initial Public Offering
Current Trends in Venture Capital • 14/05/2025 Exploring Norwest Venture Partners' Strategic Approach Through PDF Insights
Early-Stage vs. Late-Stage Investing • 22/07/2026 The 73% concentration problem: five managers, three-quarters of all venture commitments Venture capital is increasingly dominated by a handful of mega-funds. Learn how LP capital concentration reshapes early- and late-stage investing, co-investment access, pricing power, and corporate venture strategy for CEOs.
Emerging Technologies and Markets • 20/07/2026 Proxima Fusion's €411M round: what Google and RWE backing a stellarator tells allocators about deep science bets Proxima Fusion’s €411M Series B at a €2.4B valuation shows how fusion energy deep science startups can attract quant funds, tech giants, and utilities, and how founders should structure capital stacks and milestones for long-duration climate technologies.
The Process of Venture Funding • 15/07/2026 Ring-fenced vehicles and spinouts: the structural playbook investors use to back capital-heavy businesses How venture capital is evolving for capital-intensive AI, energy, and deep tech bets, and how founders can use spinouts, ring-fenced vehicles, and structured financing without losing control.
Emerging Technologies and Markets • 13/07/2026 Defense tech's $14.6B sprint: what Anduril's CEO warning means for allocators betting on military AI Defense tech and military AI funding is surging, raising the question of whether 2026 brings a structural boom or a venture capital bubble. This analysis examines valuations, exits, procurement cycles, and how CEOs and allocators should underwrite national security technology in a frothy market.
Current Trends in Venture Capital • 08/07/2026 When the IPO window opens at scale: what the 2026 listing pipeline means for exit strategy How venture-backed companies should approach IPO exit strategy in 2026: selective public markets, sponsor-to-sponsor sales, secondaries, and geographic arbitrage, with data from EY, Dealogic, PwC, Bain, and Jefferies.
Climate tech's second wave: why generalist VCs are entering the $40B cleantech market Emerging Technologies and Markets • 01/07/2026 Climate tech's second wave: why generalist VCs are entering the $40B cleantech market Cleantech venture capital investment in 2026 is shifting from niche bets to core climate infrastructure. Explore where the $40B in climate tech funding flows, how investors underwrite carbon and policy risk, and why Europe and Germany are central to this transition.
GP-led secondaries at scale: the pricing, the conflicts, and the LP playbook Innovations in VC Financing • 29/06/2026 GP-led secondaries at scale: the pricing, the conflicts, and the LP playbook Analysis of how GP-led secondaries and continuation funds are reshaping private equity and venture capital, with data, regulatory context, and an LP playbook for pricing, conflicts, and governance.
Venture Capital in Emerging Markets • 12/06/2026 Venture capital in emerging markets: where dealflow quality is outpacing the capital How venture capital in emerging markets is creating mispriced opportunities where dealflow quality outpaces capital, and how VCs can build an edge.
Current Trends in Venture Capital • 03/06/2026 The dry powder paradox: why $300B deployed in Q1 doesn't mean the market is loose A deep dive into how venture capital dry powder will be deployed in 2026, from AI mega rounds and barbell dynamics to fund construction, reserve strategies, and a practical career playbook for aspiring VCs.
Evaluating Startups for Investment • 01/06/2026 The acqui-hire is dead: M&A buyers in 2026 pay for distribution, not talent Why distribution, customer bases and user engagement now drive startup M&A value more than acqui-hire, with concrete metrics, cohort examples and data on technology acquisitions.
Emerging Technologies and Markets • 18/05/2026 Isomorphic Labs raises $2.1B: what the largest AI drug discovery round tells allocators about biotech's next chapter Analysis of Isomorphic Labs’ reported $2.1B Series B, what it signals for AI drug discovery venture capital funding, and how allocators should rethink risk, portfolio construction and sovereign capital in AI native biopharmaceutical platforms.
Current Trends in Venture Capital • 15/05/2026 Buy over build: why large corporates are paying venture premiums in 2026 Learn how a corporate buy over build M&A strategy helps CEOs accelerate innovation, justify strategic premiums, and turn corporate development into a repeatable growth engine while managing regulatory risk.
Current Trends in Venture Capital • 14/05/2026 Mid-year VC trends review: the thesis shifts founders should already be pricing in Mid-year venture capital trends in 2024: how AI megadeals, sector rotation, LP allocation shifts, and a higher cost of capital are reshaping deal pacing, term sheets, and summer fundraising strategy for CEOs.
Current Trends in Venture Capital • 13/05/2026 The IPO window is cracking open: what corp dev teams should price in How the 2026 IPO–M&A window reshapes corporate development: reserve price math, valuation discipline, global comps and board-level playbooks for CEOs competing with private equity and public markets.
Innovations in VC Financing • 11/05/2026 Secondaries as a base layer: how continuation vehicles rewrote the VC liquidity map How VC secondaries and continuation vehicles are reshaping venture capital, liquidity and governance — a strategic playbook for CEOs navigating secondary markets.
Current Trends in Venture Capital • 06/05/2026 Biotech venture in 2026: why the $600M rounds are not a bubble Biotech venture capital trends can look frothy, but late-stage mega rounds are really structured options on clinical trials and pharma M&A. Learn how Phase 2 costs, pharma acquirers, platform versus program bets, and geopolitics shape biotech valuations for CEOs and generalist VCs. by Eloise Adler
Types of Venture Funds • 04/05/2026 Lockheed Martin Ventures doubles to $1B: the corporate venture playbook gets a $600M upgrade Lockheed Martin’s 1B fund signals a new era for corporate venture capital in defense, with CVCs competing on terms, dual-use theses, and board-level strategic impact. by Leonardo Agostini
The Process of Venture Funding • 28/04/2026 The 2026 term sheet pendulum: why participating preferred is back on the table Participating preferred term sheets are reshaping venture capital outcomes. Learn how liquidation preferences, participation rights, and bridge round terms shift value between preferred and common shareholders, and how founders and boards can negotiate smarter. by Wan-Ling Chen
Types of Venture Funds • 27/04/2026 Zero Shot and the new emerging manager template: what OpenAI alumni funds teach allocators How emerging manager venture funds like Zero Shot are reshaping operator-led VC, LP diligence, and CEO-investor dynamics, with concrete mechanics and strategic implications. by Wan-Ling Chen
Current Trends in Venture Capital • 24/04/2026 Founders, read the megadeal math: what concentrated AI funding actually does to your round AI funding concentration is reshaping venture capital. Learn how LP reallocation, mega-rounds, and changing acquirer behavior affect follow-on capital, board expectations, and exit math—and what founders can do to keep negotiating power. by Leonardo Agostini
